EMD1201081 in Cetuximab-Naïve Subjects with Recurrent/Metastatic SCCHN

• Research type

  Research Study

• Full title

  A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

• IRAS ID

  30579

• Sponsor organisation

  Merck KGaA

• Eudract number

  2009-014440-10

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  N/A

• REC name

  East Midlands - Leicester South Research Ethics Committee

• REC reference

  09/H0402/106

• Date of REC Opinion

  31 Dec 2009

• REC opinion

  Favourable Opinion